Hadassah

ALS Stem Cell Trial Yielding “Impressively Positive” Findings

Thursday, Jan 2 2014

Commenting on the Phase IIa trial of NurOwn™--BrainStorm Cell Therapeutics' stem cell therapy for amyotrophic lateral sclerosis (ALS)--which is being conducted at the Hadassah Medical Organization, Prof. Dimitrios Karussis, principal investigator, reports that the safety data are "impressively positive" and that the "initial indications of clinical efficacy" are cause for optimism regarding the management of ALS and the future of cell therapies for neurodegenerative diseases in general.

Prof. Karussis, Neurologist and Director of the Multiple Sclerosis Center at Hadassah, presented some of his preliminary findings from this ongoing dose-escalating trial at the 24th International Symposium on ALS/MND in Milan, Italy. MND, Motor Neuron Disease, is the name given to a group of diseases in which the nerve cells (neurons) that control muscles undergo degeneration and die.

According to Prof. Karussis, although the final data are not yet available for publication because the trial is still ongoing, researchers have met with only minimal and transient adverse effects, even though the patients in the study were given the treatment both intrathecally (into the cerebrospinal fluid by injection into the subarachnoid space of the spinal cord) and intramuscularly, with up to double the dose of the stem cells given in the Phase I trial.

At the conclusion of the clinical trial, BrainStorm will release the complete set of data and corresponding analyses.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Oct 18 2018

Advocacy Update | Advocate for Breast Cancer Month

At Hadassah, we're using three proven strategies to fight breast cancer: education & awareness, domestic advocacy, and support for groundbreaking research at the Hadassah Medical Organization (HMO).

READ MORE ›
alt_text

Monday, Oct 15 2018

Hadassah Dedicates Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem News Release

Hadassah unveiled the Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem on Friday, October 12th in Jerusalem, announced Ellen Hershkin, National President, Hadassah, the Women’s Zionist Organization of America, Inc.

READ MORE ›
alt_text

Monday, Oct 15 2018

Hadassah Dedicates Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem

Hadassah unveiled the Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem on Friday, October 12th in Jerusalem, announced Ellen Hershkin, National President, Hadassah, the Women’s Zionist Organization of America, Inc.

READ MORE ›
alt_text

Friday, Oct 12 2018

New Zealand Scholarship Winner Comes to Hadassah Hospital

Describing it as a “life-changing experience,” Dinithi Seneviratne, a New Zealand health care professional, recently spent several weeks as an observer in the Pediatric Emergency Department at Hadassah Hospital in Ein Kerem, Jerusalem.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More